Regenicin Inc. (RGIN)

Overview

Regenicin, Inc., originally known as Windstar, Inc., has strategically positioned itself in the biotechnology sector with a strong focus on the development and commercialization of advanced skin substitute technologies. Founded in 2007 and undergoing a name change to better reflect its mission in July 2010, Regenicin is dedicated to innovating within the field of regenerative medicine. With its headquarters nestled in Little Falls, New Jersey, the company aims to revolutionize the treatment of burns, chronic wounds, and various dermatological conditions through its pioneering products. By emphasizing the restoration of healthy human skin qualities, Regenicin not only offers solutions for immediate medical needs but also contributes to the broader scope of improving patients' quality of life post-injury or surgery.

Products and Services

• NovaDerm

  NovaDerm represents Regenicin's forefront innovation in the field of regenerative medicine. Designed as a multi-layered tissue-engineered living skin, this cultured skin substitute product is primarily targeted for the treatment of extensive burns. NovaDerm leverages cutting-edge technology to mimic natural skin, offering hope and enhanced recovery possibilities for patients suffering from severe burns. Its capacity to integrate with the patient's own skin accelerates the healing process, thus reducing the risk of infection and other complications associated with traditional skin grafts.

• TempaDerm

  TempaDerm serves as an essential component of Regenicin's product portfolio, specifically aimed at treating smaller wound areas including ulcers. This product emerges as a crucial solution for patients dealing with chronic wounds, offering a tissue-engineered alternative that promotes healing and reduces the chances of wound-related complications. TempaDerm's innovative approach lies in its adaptability to various types of smaller wounds, making it a versatile option for medical professionals in both acute and long-term care settings.